In a significant move for the field of brain health diagnostics, C₂N Diagnostics, LLC, a pioneer in developing advanced diagnostic solutions for Alzheimer’s disease, has secured an investment of up to $15 million from Eisai Inc., a globally recognized human health care company. This strategic partnership underscores a shared commitment between the two firms to […]
Biogen, a leading US biotechnology firm, has reached a significant agreement to acquire Pfizer’s neurology drug candidate, PF-04958242, which is being developed to address cognitive impairment associated with schizophrenia (CIAS). The deal, potentially worth almost $600 million, includes an upfront payment of $75 million, with additional milestone payments and royalties that could total up to […]
The University of Antwerp in Belgium has initiated an innovative clinical trial aimed at mitigating the cognitive deficits associated with breast cancer treatment, marking a significant advancement in the field. This trial will utilize a video game-based training and assessment tool, scientifically designed by the UK-based My Cognition, which specializes in cognitive health. Addressing Cognitive […]